2 completed, 1 recruiting, 1 terminated. 4 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | City of Hope Medical Center | 9 | 2023-07-20 | 2026-02-04 |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 35 | 2015-10-13 | 2022-10-28 |
Lymphoma, Large B-Cell, Diffuse (4) · Chromosome 17 deletion (1) · Hematologic Neoplasms (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, B-Cell (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma, Non-Hodgkin (3) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Magnetic Resonance Spectroscopy (2) · CTL019 chimeric antigen receptor (1) · Drug Therapy (1) · Fluorodeoxyglucose F18 (1) · Immunotherapy, Adoptive (1) · Leukapheresis (1) · Radiation (1) · Specimen Handling (1) · duvelisib (1) · tisagenlecleucel (1)
City of Hope Medical Center (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Rutgers, The State University of New Jersey (1)
United States (4)
Edmund K Waller, MD, PhD (1) · Jason Westin (1) · Roger Strair (1) · Savita V Dandapani (1)
P30CA033572 (1), P30CA072720 (1), P30CA138292 (1)